ClinicalTrials.gov
ClinicalTrials.gov Menu

The Effect of PinnoThin on Satiety and Food Intake (PinnoThin)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01034605
Recruitment Status : Completed
First Posted : December 17, 2009
Last Update Posted : August 30, 2012
Sponsor:
Information provided by (Responsible Party):
Maastricht University Medical Center

Brief Summary:
Based upon an increased secretion of gastrointestinal satiety hormones (CCK, GLP-1), PinnoThin is hypothesized to be more satiating, and to limit energy intake in humans. Therefore, the objective of this study is to investigate whether PinnoThin leads to an increase in satiety as determined by VAS ratings? Additionally, does PinnoThin consumed during breakfast, in comparison to placebo, in overweight women, lead to a decrease in energy intake during an ad libitum lunch?

Condition or disease Intervention/treatment Phase
Obesity Dietary Supplement: PinnoThin Not Applicable

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 40 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Double (Participant, Investigator)
Official Title: The Effect of PinnoThin on Satiety and Food Intake
Study Start Date : December 2008
Actual Primary Completion Date : January 2010
Actual Study Completion Date : January 2010

Arm Intervention/treatment
Experimental: inulin
oligofructose
Dietary Supplement: PinnoThin
6.0 gram of the oil extract from the korean pine nut (PinnoThin) as a single dose



Primary Outcome Measures :
  1. appetite profile ratings [ Time Frame: 10 timepoints ]

Secondary Outcome Measures :
  1. energy intake [ Time Frame: 3.5 hours after PinnoThin ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 45 Years   (Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • age over 18 and under 45
  • women
  • BMI over 23 and under 30
  • breakfast eaters

Exclusion Criteria:

  • men
  • age under 18 and over 45
  • BMI under 23 and over 30
  • use of medication
  • pregnant and breastfeeding

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01034605


Locations
Netherlands
Maastricht University
Maastricht, Limburg, Netherlands, 6229ER
Sponsors and Collaborators
Maastricht University Medical Center
Investigators
Principal Investigator: Klaas R Westerterp, Prof NUTRIM

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: Maastricht University Medical Center
ClinicalTrials.gov Identifier: NCT01034605     History of Changes
Other Study ID Numbers: HumBio_Westerterp08
First Posted: December 17, 2009    Key Record Dates
Last Update Posted: August 30, 2012
Last Verified: August 2012